Study of 18F-FAPI Applied to Gastrointestinal Cancer

Comparative Study of 18F-FAPI and 18F-FDG PET/CT for Gastrointestinal Cancer

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05788874

Enrollment

Registered

2023-03-29

Start date

2023-05-31

Completion date

2024-12-31

Last updated

2023-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancer

Brief summary

Comparison of tumor volume, number, and SUVmax of different primary foci (gastric, duodenal, and colon cancer), lymph node metastases (neck and supraclavicular, mediastinal, abdominal, and pelvic), and distant metastases (brain, lung, liver, bone, pleura, and peritoneum) detected by 18F-FAPI versus 18F-FDG PET/CT imaging.

Interventions

DIAGNOSTIC_TEST18F-FAPI and 18F-FDG PET/CT

18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with high clinical suspicion of gastrointestinal tumor and negative 18F-FDG at first diagnosis * Post-treatment patients with high clinical suspicion of recurrence or metastasis and negative 18F-FDG

Exclusion criteria

* The diagnosis can be clarified by 18F-FDG PET/CT examination * The presence of recurrence or metastasis can be clarified by 18F-FDG PET/CT examination

Design outcomes

Primary

Measure	Time frame	Description
SUVmax	1 day (During the inspection)	Measurement of the maximum standardized uptake value of the lesion

Contacts

Primary ContactYan Li

29396779@qq.com0086-15829364429

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026